16 September 2026 editorial review · Item
SAB-142 (fully human anti-thymocyte globulin): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: SAB-142's four-treated-person Day-120 signal is sponsor-reported. Corrected rabbit-ATG “only once” assertions and press-release source classification. PRISE's estimated 1 September start has passed while the registry remains not yet recruiting. Repeat-course safety and efficacy remain unproven.
- Registry NCT07187531: RECRUITING; updated 2026-08-24; enrollment 159 (ESTIMATED); primary completion 2027-11 (ESTIMATED); results not posted in retrieved record.
- Registry NCT07670650: NOT_YET_RECRUITING; updated 2026-06-26; enrollment 108 (ESTIMATED); primary completion 2029-03-01 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 (manufacturer); SAB BIO to Present Data on SAB-142 at the American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting (manufacturer).